Single chain Fv antibodies against the 25-35 Aβ fragment inhibit aggregation and toxicity of Aβ42

Andleeb Zameer, Philip Schulz, Min S. Wang, Michael Sierks

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Alzheimer's disease (AD) is characterized by the deposition of amyloid-β (Aβ) protein in the brain. Immunization studies have demonstrated that anti-Aβ antibodies reduce Aβ deposition and improve clinical symptoms seen in AD. However, conventional antibody-based therapies risk an inflammatory response that can result in meningoencephalitis and cerebral hemorrhage. Here we report on the development of human-based single chain variable domain antibody fragments (scFvs) directed against the Aβ 25-35 region as potential therapeutics for AD that do not risk an inflammatory response. The 25-35 region of Aβ represents a promising therapeutic target since it promotes aggregation and is highly toxic. Two scFvs with differing affinities for Aβ were studied, and both inhibited aggregation of Aβ42 as determined by thioflavin T binding assay and atomic force microscopy analysis and blocked Aβ-induced toxicity toward human neuroblastoma SH-SY5Y cells as determined by MTT and LDH release assays. These results provide additional evidence that scFvs against Aβ provide an attractive alternative to more conventional antibody-based therapeutics for controlling aggregation and toxicity of Aβ.

Original languageEnglish (US)
Pages (from-to)11532-11539
Number of pages8
JournalBiochemistry
Volume45
Issue number38
DOIs
StatePublished - Sep 26 2006

Fingerprint

Single-Chain Antibodies
Toxicity
Agglomeration
Alzheimer Disease
Antibodies
Assays
Immunization
Serum Amyloid A Protein
Immunoglobulin Fragments
Poisons
Meningoencephalitis
Atomic Force Microscopy
Atomic force microscopy
Brain
Cerebral Hemorrhage
Human Development
Therapeutics
Neuroblastoma
Anti-Idiotypic Antibodies

ASJC Scopus subject areas

  • Biochemistry

Cite this

Single chain Fv antibodies against the 25-35 Aβ fragment inhibit aggregation and toxicity of Aβ42. / Zameer, Andleeb; Schulz, Philip; Wang, Min S.; Sierks, Michael.

In: Biochemistry, Vol. 45, No. 38, 26.09.2006, p. 11532-11539.

Research output: Contribution to journalArticle

Zameer, Andleeb ; Schulz, Philip ; Wang, Min S. ; Sierks, Michael. / Single chain Fv antibodies against the 25-35 Aβ fragment inhibit aggregation and toxicity of Aβ42. In: Biochemistry. 2006 ; Vol. 45, No. 38. pp. 11532-11539.
@article{d24a33a3b448416187e63c7d258e56f7,
title = "Single chain Fv antibodies against the 25-35 Aβ fragment inhibit aggregation and toxicity of Aβ42",
abstract = "Alzheimer's disease (AD) is characterized by the deposition of amyloid-β (Aβ) protein in the brain. Immunization studies have demonstrated that anti-Aβ antibodies reduce Aβ deposition and improve clinical symptoms seen in AD. However, conventional antibody-based therapies risk an inflammatory response that can result in meningoencephalitis and cerebral hemorrhage. Here we report on the development of human-based single chain variable domain antibody fragments (scFvs) directed against the Aβ 25-35 region as potential therapeutics for AD that do not risk an inflammatory response. The 25-35 region of Aβ represents a promising therapeutic target since it promotes aggregation and is highly toxic. Two scFvs with differing affinities for Aβ were studied, and both inhibited aggregation of Aβ42 as determined by thioflavin T binding assay and atomic force microscopy analysis and blocked Aβ-induced toxicity toward human neuroblastoma SH-SY5Y cells as determined by MTT and LDH release assays. These results provide additional evidence that scFvs against Aβ provide an attractive alternative to more conventional antibody-based therapeutics for controlling aggregation and toxicity of Aβ.",
author = "Andleeb Zameer and Philip Schulz and Wang, {Min S.} and Michael Sierks",
year = "2006",
month = "9",
day = "26",
doi = "10.1021/bi060601o",
language = "English (US)",
volume = "45",
pages = "11532--11539",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "38",

}

TY - JOUR

T1 - Single chain Fv antibodies against the 25-35 Aβ fragment inhibit aggregation and toxicity of Aβ42

AU - Zameer, Andleeb

AU - Schulz, Philip

AU - Wang, Min S.

AU - Sierks, Michael

PY - 2006/9/26

Y1 - 2006/9/26

N2 - Alzheimer's disease (AD) is characterized by the deposition of amyloid-β (Aβ) protein in the brain. Immunization studies have demonstrated that anti-Aβ antibodies reduce Aβ deposition and improve clinical symptoms seen in AD. However, conventional antibody-based therapies risk an inflammatory response that can result in meningoencephalitis and cerebral hemorrhage. Here we report on the development of human-based single chain variable domain antibody fragments (scFvs) directed against the Aβ 25-35 region as potential therapeutics for AD that do not risk an inflammatory response. The 25-35 region of Aβ represents a promising therapeutic target since it promotes aggregation and is highly toxic. Two scFvs with differing affinities for Aβ were studied, and both inhibited aggregation of Aβ42 as determined by thioflavin T binding assay and atomic force microscopy analysis and blocked Aβ-induced toxicity toward human neuroblastoma SH-SY5Y cells as determined by MTT and LDH release assays. These results provide additional evidence that scFvs against Aβ provide an attractive alternative to more conventional antibody-based therapeutics for controlling aggregation and toxicity of Aβ.

AB - Alzheimer's disease (AD) is characterized by the deposition of amyloid-β (Aβ) protein in the brain. Immunization studies have demonstrated that anti-Aβ antibodies reduce Aβ deposition and improve clinical symptoms seen in AD. However, conventional antibody-based therapies risk an inflammatory response that can result in meningoencephalitis and cerebral hemorrhage. Here we report on the development of human-based single chain variable domain antibody fragments (scFvs) directed against the Aβ 25-35 region as potential therapeutics for AD that do not risk an inflammatory response. The 25-35 region of Aβ represents a promising therapeutic target since it promotes aggregation and is highly toxic. Two scFvs with differing affinities for Aβ were studied, and both inhibited aggregation of Aβ42 as determined by thioflavin T binding assay and atomic force microscopy analysis and blocked Aβ-induced toxicity toward human neuroblastoma SH-SY5Y cells as determined by MTT and LDH release assays. These results provide additional evidence that scFvs against Aβ provide an attractive alternative to more conventional antibody-based therapeutics for controlling aggregation and toxicity of Aβ.

UR - http://www.scopus.com/inward/record.url?scp=33749034211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749034211&partnerID=8YFLogxK

U2 - 10.1021/bi060601o

DO - 10.1021/bi060601o

M3 - Article

C2 - 16981713

AN - SCOPUS:33749034211

VL - 45

SP - 11532

EP - 11539

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 38

ER -